St. Jude Care & Treatment

Menu

Close

Recruiting

PEPN2312: Imetelstat with Fludarabine and Cytarabine for AML, MDS, or JMML

About this study 

Acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and juvenile myelomonocytic leukemia (JMML) are types of cancer that occur in the bone marrow. AML, MDS, and JMML are considered high risk when they come back (relapse) or when they do not respond to standard treatment (refractory).

Imetelstat is a medicine that may stop the growth of cancer cells. In this study, doctors will use the chemotherapy drugs cytarabine and fludarabine plus imetelstat to treat AML, MDS, and JMML. This treatment will take about 2 months.

This study will help doctors learn more about using imetelstat to treat AML, MDS, and JMML that comes back or has not responded to treatment. Patients will provide bone marrow and blood for testing.

Eligibility overview 

  • Between 12 months and 18 years old
  • Relapsed AML, MDS, or JMML
  • Have not received imetelstat

Request a referralLearn about clinical research

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Overview

Full title:

A Phase 1 Study of GRN163L (Imetelstat) in Combination with Fludarabine and Cytarabine for Patients with Acute Myeloid Leukemia that is in Second or Greater Relapse or that is Refractory to Relapse Therapy; Myelodysplastic Syndrome or Juvenile Myelomonocytic Leukemia in First or Greater Relapse or is Refractory to Relapse Therapy

Study goal:

To find the safest dose of imetelstat that can be given with fludarabine and cytarabine to stop the growth of cancer cells.  

Diagnosis:

Acute myeloid leukemia, myelodysplastic syndromes, juvenile myelomonocytic leukemia

Age:

Between 12 months and 18 years old

Clinical trials categories:

Juvenile Myelomonocytic Leukemia Acute Myeloid Leukemia (AML) Childhood Cancer Leukemia Myelodysplastic Syndromes

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.

 

Learn more